Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in SARS-CoV-2 Pneumonia
NCT04382625Phase 4Withdrawn
- Sponsor
- Kootenai Health
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in COVID-19 pneumonia (2 arms), sponsored by Kootenai Health. Primary endpoint: Change from Baseline Oxygenation on Day 1 to Day 5. Planned start Oct 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04382625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382625.